Recommendations for preventing medication errors in cancer chemotherapy are made. Before a health care provider is granted privileges to prescribe, dispense, or administer antineoplastic agents, he or she should undergo a tailored educational program and possibly testing or certification. Appropriate reference materials should be developed. Each institution should develop a dose-verification process with as many independent checks as possible. A detailed checklist covering prescribing, transcribing, dispensing, and administration should be used. Oral orders are not acceptable. All doses should be calculated independently by the physician, the pharmacist, and the nurse. Dosage limits should be established and a review process set up for doses that exceed the limits. These limits should be entered into pharmacy computer systems, listed on preprinted order forms, stated on the product packaging, placed in strategic locations in the institution, and communicated to employees. The prescribing vocabulary must be standardized. Acronyms, abbreviations, and brand names must be avoided and steps taken to avoid other sources of confusion in the written orders, such as trailing zeros. Preprinted antineoplastic drug order forms containing checklists can help avoid errors. Manufacturers should be encouraged to avoid or eliminate ambiguities in drug names and dosing information. Patients must be educated about all aspects of their cancer chemotherapy, as patients represent a last line of defense against errors. An interdisciplinary team at each practice site should review every medication error reported. Pharmacists should be involved at all sites where antineoplastic agents are dispensed. Although it may not be possible to eliminate all medication errors in cancer chemotherapy, the risk can be minimized through specific steps. Because of their training and experience, pharmacists should take the lead in this effort.

 

This article has been cited by other articles:

				B. C. O'Neal, J. C. Worden, and R. J. Couldry Telepharmacy and bar-code technology in an i.v. chemotherapy admixture area Am. J. Health Syst. Pharm., July 1, 2009; 66(13): 1211 - 1217. [Abstract] [Full Text] [PDF]

				M. D. Small, B. Pharm, A. Barrett, and G. M Price The impact of computerized prescribing on error rate in a department of Oncology/Hematology Journal of Oncology Pharmacy Practice, December 1, 2008; 14(4): 181 - 187. [Abstract] [PDF]

				P. E Johnson, C. R Chambers, and A. J Vaida Oncology medication safety: A 3D status report 2008 Journal of Oncology Pharmacy Practice, December 1, 2008; 14(4): 169 - 180. [Abstract] [PDF]

				C. D. Ford, J. Killebrew, P. Fugitt, J. Jacobsen, and E. M. Prystas Study of Medication Errors on a Community Hospital Oncology Ward J. Oncol. Pract, July 1, 2006; 2(4): 149 - 154. [Abstract] [Full Text] [PDF]

				P. Legant Oncologists and Medical Malpractice J. Oncol. Pract, July 1, 2006; 2(4): 164 - 169. [Full Text] [PDF]

				P. Bonnabry, L. Cingria, M. Ackermann, F. Sadeghipour, L. Bigler, and N. Mach Use of a prospective risk analysis method to improve the safety of the cancer chemotherapy process Int. J. Qual. Health Care, February 1, 2006; 18(1): 9 - 16. [Abstract] [Full Text] [PDF]

				A. M. Birner, M. K. Bedell, J. T. Avery, and M. S. Ernstoff Program to Support Safe Administration of Oral Chemotherapy J. Oncol. Pract, January 1, 2006; 2(1): 5 - 6. [Full Text] [PDF]

				C. Dinning, P. Branowicki, J. B. O'Neill, B. L. Marino, and A. Billett Chemotherapy Error Reduction: A Multidisciplinary Approach to Create Templated Order Sets Journal of Pediatric Oncology Nursing, January 1, 2005; 22(1): 20 - 30. [Abstract] [PDF]

				P. Gilbar, M. Dooley, and J.-a. Brien Inadvertent intrathecal administration of vincristine: are we fulfilling our roles as oncology pharmacists? Journal of Oncology Pharmacy Practice, December 1, 2004; 10(4): 187 - 189. [PDF]

				R. B. Womer, E. Tracy, W. Soo-Hoo, B. Bickert, S. DiTaranto, and J. H. Barnsteiner Multidisciplinary Systems Approach to Chemotherapy Safety: Rebuilding Processes and Holding the Gains J. Clin. Oncol., December 15, 2002; 20(24): 4705 - 4712. [Abstract] [Full Text] [PDF]

				K. A. Grindrod, C. R Chambers, and J. Hicks Updating a survey for medication error prevention Journal of Oncology Pharmacy Practice, December 1, 2002; 8(4): 105 - 117. [Abstract] [PDF]

				D. D. Kloth Prevention of Chemotherapy Medication Errors Journal of Pharmacy Practice, February 1, 2002; 15(1): 17 - 31. [Abstract] [PDF]

				M. J. Dooley and J. Vernon Reproducibility of treatment methodologies detailed in contemporary clinical trial reports Journal of Oncology Pharmacy Practice, June 1, 2000; 6(2): 50 - 54. [Abstract] [PDF]

				J. C Roscoe, E. Goransson, M. Slancar, J. Smith, S. Taylor, and S. Tyson A multidisciplinary approach to ensure safety in the prescribing and administration of chemotherapy Journal of Oncology Pharmacy Practice, June 1, 2000; 6(2): 60 - 63. [Abstract] [PDF]

				M. Tran The impact of introducing pre-printed chemotherapy medication charts to a day chemotherapy unit Journal of Oncology Pharmacy Practice, June 1, 2000; 6(2): 64 - 69. [Abstract] [PDF]

				G. D. Schiff and T. D. Rucker Computerized Prescribing: Building the Electronic Infrastructure for Better Medication Usage JAMA, April 1, 1998; 279(13): 1024 - 1029. [Abstract] [Full Text] [PDF]

				D. R. Kohler, M. J. Montello, L. Green, C. Huntley, J. L. High, A. Fallavollita, and B. R. Goldspiel Standardizing the expression and nomenclature of cancer treatment regimens Journal of Oncology Pharmacy Practice, March 1, 1998; 4(1): 23 - 31. [Abstract] [PDF]